Asia
Companies from across the globe provide updates on their business and pipelines.
Nourianz (istradefylline) was given the thumbs-up as an add-on treatment to levodopa/carbidopa in adults with Parkinson’s disease who experience “OFF” episodes.
Leaders from across the pharmaceutical industry are decrying negative actions taken by government agencies and universities against Chinese researchers in the United States.
Biocon Ltd, Asia’s premier biopharmaceuticals company, Biocon Ltd announced that it’s subsidiary in Malaysia, Biocon Sdn.
Biopharma companies large and small are involved in numerous clinical trials. Here’s a look at some of the top stories from last week.
Singapore molecular diagnostics groups INEX Innovations Exchange Pte. Ltd. (INEX) and Nova Satra Dx Pte. Ltd. (Nova Satra) announced the merger of the two companies to create INEX INNOVATE.
Companies from across the globe provide updates on their business and pipelines.
Over a 12-week course of treatment, Teva said fremanezumab provided patients with statistically significant reductions in monthly average number of migraine days. The results of the study were published in Lancet.
WuXi Biologics (Cayman) Inc. announced its unaudited interim results for the six months ended June 30, 2019.
Xylonix announced it has signed a Memorandum of Understanding (MOU) with BioGemex to jointly develop a new pre-treatment point-of-care diagnostic, XDX-01, to better predict a patient’s response to T-cell mediated cancer immunotherapies in solid tumors.
PRESS RELEASES